AMRC.org

Join us for an in-depth conversation on effective strategies for growing your site within today’s evolving clinical research landscape. Hear from subject matter experts representing 3 leading site networks as they share proven approaches to expanding site business by leveraging multi-site network models.

By Patrick Cooney, for AMRC FEDERAL AGENCY NEWS FY27 Trump Budget Raises NIH Funding Concerns Again The Trump Administration’s fiscal year 2027 budget proposal signals a renewed push to reshape federal health policy priorities in ways that could significantly affect the clinical research ecosystem. Congress rejected similar proposals in FY26. In an election year, given the makeup of the current C…

A Strategic Alliance: Joining AMRC as a Founding Member Joining AMRC as a founding member in 2024 was an easy decision for Chief Development Officer Jeff Kingsley and the team at Centricity Research. They understood that working with AMRC members would give sites “a big voice with sponsors and regulators,” he says. A maturing industry, bolstered by an organization like AMRC, gives sites the abili…

17 March 2026: The Association of Multisite Research Corporations (AMRC) today announces that Panthera and ObjectiveHealth have joined the organisation, bringing total membership to 19 multisite clinical research corporations (MCRCs), up from 14 members just 12 months ago. This continued growth reflects increasing industry recognition that multisite organisations play a central role in delivering…

By Patrick Cooney, for AMRC FEDERAL AGENCY NEWS Single Pivotal Trial for Drug Approvals Reaction from Congress has been muted since the U.S. Food and Drug Administration (FDA) announced its decision to move toward a single pivotal trial for drug approvals. No new legislation has been introduced, but several lawmakers have expressed scrutiny of FDA decision-making more broadly, which could extend …

Re: Docket OSTP-TECH-2025-0100 The Association of Multisite Research Corporations (AMRC) appreciates the opportunity to comment on this important Federal policy update on accelerating the American scientific enterprise. AMRC applauds any initiative to advance science and clinical trials to the benefit of patients. About the Association of Multisite Research Corporations (AMRC) Founded in 2025, AM…

Patricio Casillas’s journey into the world of clinical trials had some zigs and zags along the way, yet he somehow always suspected he’d end up on the research and development (R&D) side of the equation. Patricio brings over 20 years of leadership experience in healthcare across various sectors including pharma, med device, value-based primary care, hospital, pharmacy, and DME. He earned a B.S. i…

By Patrick Cooney, for AMRC FEDERAL AGENCY NEWS FDA Refusal to Review Moderna’s Flu Vaccine Raises Questions The U.S. Food and Drug Administration’s recent decision to decline review of Moderna’s investigational mRNA-based seasonal influenza vaccine (mRNA-1010) has generated significant discussion across the clinical-research ecosystem, with implications for trial design, regulatory predictabilit…

It was the photos that caught her eye. Vibrant images of patients, both adults and children, lining the walls of the interview room. For Kari Delahunty, those faces represented more than statistics, they were stories of lives changed through clinical trials. “During my very first interview in the clinical research field, I noticed those photos,” she recalls. Now, two decades later and just weeks …

By Patrick Cooney, for AMRC FEDERAL AGENCY NEWS FDA Releases Guidance on Modernizing Statistical Methods in Clinical Trials On January 12, 2026, the U.S. Food and Drug Administration (FDA) issued a draft guidance titled Use of Bayesian Methodology in Clinical Trials of Drugs and Biologics; Draft Guidance for Industry, marking a significant step toward modernizing statistical approaches in clinica…

At the beginning of 2025, AMRC set out to champion the multisite clinical research corporation (MCRC) model and to ensure that Sponsors, CROs, policymakers, and the wider industry understood its advantages. That work focused on the structural challenges facing clinical research, including investigator and coordinator burnout, fragmented site infrastructure, increasing protocol complexity, and the…

Join us as we present the findings of AMRC's 2025 industry consultation on quality in clinical research and outline the steps the association will take to define and recognise quality in practice.

Pratia LLC, part of Humaneva Group, announced in December 2025 the acquisition of a majority stake in P1 Trials, a U.S.-based early-phase-community oncology clinical research network.

2026 marks the end of trial-and-error vendor models. Sponsors are consolidating relationships and choosing partners who can plan, scale, and deliver consistently across pipelines.

Soothsayers like Nostradamus, Mother Shipton , and the Amazing Kreskin have a decidedly mixed record when it comes to predicting the future. Still, it’s an irresistible human impulse, especially as a year ends, to peer into the proverbial crystal ball in the hopes of seeing what’s coming down the road.

By 2026, the clinical research industry will look markedly different. This won’t come from a single breakthrough, but because of a collective shift in how Sponsors, sites, and partners choose to work together. Across the Association of Multisite Research Corporations (AMRC) members, a clear message emerges: the era of experimentation is ending. The era of strategic choice has begun.

Tekton Research’s recent announcement of two new research sites in New Carlisle, Ohio, and Englewood, New Jersey, reflects more than geographic growth. It offers a clear view into how multisite clinical research corporations (MCRCs) are evolving from collections of sites into scalable research infrastructure designed for speed, quality, and access.

While he’s a firm believer in the entire clinical trial process, for Carlos Orantes, Chief Executive Officer at Alcanza Clinical Research, there’s an unmistakable ‘magic’ to be found in late-stage trials. “You’re that much closer to bringing lifesaving and enhancing drugs and devices to patients by collaborating with other dedicated professionals,” he says.

While he’s a firm believer in the entire clinical trial process, for Carlos Orantes, Chief Executive Officer at Alcanza Clinical Research, there’s an unmistakable ‘magic’ to be found in late-stage trials. “You’re that much closer to bringing lifesaving and enhancing drugs and devices to patients by collaborating with other dedicated professionals,” he says.

The Association of Multisite Research Corporations (AMRC) today announced the addition of three new members,Rovia Clinical Research, K2 Medical Research, and Eximia, further expanding its representation of leading multisite research organizations across the United States and internationally.